Benzinga
Benzinga
Benzinga
miércoles, septiembre 30

Jazz Pharmaceuticals PLC

JAZZNASDAQ
Trade with Public
Trade with Public
$234.00
1.650.71%
Últ. Act.: Sep 30, 9:09 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

18Buy
2Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$263Upside to Avg. PT+12.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026CitigroupGeoff MeachamInitiateBuy$325
Sep 24, 2026Goldman SachsAndrea NewkirkReinstatesBuy$337
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.
Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.
Benzinga Newsdesk

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Avi Kapoor

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved